Publicacións en colaboración con investigadores/as de Dalhousie University (27)

2024

  1. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial

    The Journal of infectious diseases, Vol. 229, Núm. 1, pp. 95-107

2023

  1. Age Differences in Comorbidities, Presenting Symptoms, and Outcomes of Influenza Illness Requiring Hospitalization: A Worldwide Perspective From the Global Influenza Hospital Surveillance Network

    Open Forum Infectious Diseases

  2. Diminishing benefits of urban living for children and adolescents’ growth and development

    Nature, Vol. 615, Núm. 7954, pp. 874-883

  3. Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age

    The Journal of infectious diseases, Vol. 227, Núm. 11, pp. 1293-1302

2021

  1. Association of Rare CYP39A1 Variants with Exfoliation Syndrome Involving the Anterior Chamber of the Eye

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 8, pp. 753-764

  2. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial

    Vaccine, Vol. 39, Núm. 11, pp. 1598-1608

2020

  1. Complicated hospitalization due to influenza: Results from the Global Hospital Influenza Network for the 2017-2018 season

    BMC Infectious Diseases, Vol. 20, Núm. 1

  2. Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial

    Vaccine, Vol. 38, Núm. 8, pp. 2095-2104

  3. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial

    Vaccine, Vol. 38, Núm. 8, pp. 2105-2114

  4. Repositioning of the global epicentre of non-optimal cholesterol

    Nature, Vol. 582, Núm. 7810, pp. 73-77

2019

  1. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

    Human Vaccines and Immunotherapeutics, Vol. 15, Núm. 12, pp. 2865-2872

  2. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 74, Núm. 8, pp. 1231-1238

  3. Rising rural body-mass index is the main driver of the global obesity epidemic in adults

    Nature

  4. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials

    Vaccine, Vol. 37, Núm. 18, pp. 2482-2493

2018

  1. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants

    International Journal of Epidemiology, Vol. 47, Núm. 3, pp. 872-883i

2017

  1. Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci

    Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004

  2. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants

    The Lancet, Vol. 389, Núm. 10064, pp. 37-55

  3. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults

    The Lancet, Vol. 390, Núm. 10113, pp. 2627-2642

2016

  1. A century of trends in adult human height

    eLife, Vol. 5, Núm. 2016JULY

  2. A century of trends in adult human height

    eLife, Vol. 5